JP4050317B2 - Ｉｌ−１０含有医薬組成物 - Google Patents
Ｉｌ−１０含有医薬組成物 Download PDFInfo
- Publication number
- JP4050317B2 JP4050317B2 JP50824697A JP50824697A JP4050317B2 JP 4050317 B2 JP4050317 B2 JP 4050317B2 JP 50824697 A JP50824697 A JP 50824697A JP 50824697 A JP50824697 A JP 50824697A JP 4050317 B2 JP4050317 B2 JP 4050317B2
- Authority
- JP
- Japan
- Prior art keywords
- wounds
- wound
- pharmaceutical composition
- healing
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000174 Interleukin-10 Proteins 0.000 title claims abstract description 54
- 102000003814 Interleukin-10 Human genes 0.000 title claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 71
- 206010052428 Wound Diseases 0.000 claims abstract description 70
- 230000035876 healing Effects 0.000 claims abstract description 24
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 16
- 239000012634 fragment Substances 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 230000002829 reductive effect Effects 0.000 claims abstract description 12
- 230000037390 scarring Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 9
- 230000036573 scar formation Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 231100000241 scar Toxicity 0.000 description 12
- 239000000835 fiber Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 102000052620 human IL10 Human genes 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000037311 normal skin Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Invalid Beds And Related Equipment (AREA)
- Eye Examination Apparatus (AREA)
- Prostheses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9516287.1 | 1995-08-09 | ||
| GB9516287A GB2304047A (en) | 1995-08-09 | 1995-08-09 | Pharmaceutical compositions containing cytokines |
| PCT/GB1996/001930 WO1997005894A1 (en) | 1995-08-09 | 1996-08-08 | Pharmaceutical composition containing il-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH11510505A JPH11510505A (ja) | 1999-09-14 |
| JPH11510505A5 JPH11510505A5 (enExample) | 2004-09-09 |
| JP4050317B2 true JP4050317B2 (ja) | 2008-02-20 |
Family
ID=10778967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50824697A Expired - Fee Related JP4050317B2 (ja) | 1995-08-09 | 1996-08-08 | Ｉｌ−１０含有医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6387364B1 (enExample) |
| EP (1) | EP0871473B1 (enExample) |
| JP (1) | JP4050317B2 (enExample) |
| AT (1) | ATE229814T1 (enExample) |
| AU (1) | AU719089B2 (enExample) |
| CA (1) | CA2229078C (enExample) |
| DE (1) | DE69625516T2 (enExample) |
| DK (1) | DK0871473T3 (enExample) |
| ES (1) | ES2187665T3 (enExample) |
| GB (1) | GB2304047A (enExample) |
| PT (1) | PT871473E (enExample) |
| WO (1) | WO1997005894A1 (enExample) |
| ZA (1) | ZA966744B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001505219A (ja) * | 1996-12-04 | 2001-04-17 | ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター | 創傷の治癒および線維症の治療 |
| WO1998033516A1 (en) * | 1997-02-05 | 1998-08-06 | Schering Corporation | Use of il-4 and/or il-10 to treat proliferative glomerulonephritis |
| AU6951300A (en) * | 1999-09-08 | 2001-04-10 | Schering Corporation | Novel uses of mammalian ccr6 receptors and related reagents |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| ATE516820T1 (de) | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
| WO2003062373A2 (en) * | 2001-10-18 | 2003-07-31 | The Children's Hospital Of Philadelphia | Methods and materials for the recruitment of endothelial cells |
| JP4790609B2 (ja) * | 2003-07-15 | 2011-10-12 | バーイラン ユニバーシティー | 創傷治癒のための方法及び薬剤組成物 |
| WO2005013885A2 (en) | 2003-08-07 | 2005-02-17 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
| GB0500643D0 (en) * | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| GB0524103D0 (en) * | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
| NO346530B1 (no) | 2006-09-28 | 2022-09-26 | Merck Sharp & Dohme | Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene. |
| KR20150072458A (ko) | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
| EP2653166A3 (en) * | 2007-07-30 | 2014-08-27 | Healor Ltd. | Pharmaceutical composition and related methods |
| GB0724231D0 (en) * | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| CA2710375A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
| EP2252690A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| EP2234656A2 (en) | 2007-12-21 | 2010-10-06 | Coda Therapeutics, Inc. | Improved medical devices |
| MX2010010431A (es) * | 2008-03-25 | 2010-11-25 | Paloma Pharmaceuticals Inc | Metodos para tratar desordenes fibroticos. |
| CN102256625B (zh) | 2008-12-17 | 2013-11-20 | 默沙东公司 | 单和双peg il10的生产和用途 |
| ES2601827T3 (es) * | 2009-02-24 | 2017-02-16 | Arava Bio-Tech Ltd. | Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones |
| WO2012112791A1 (en) | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| US20140112898A1 (en) * | 2011-03-31 | 2014-04-24 | President And Fellows Of Harvard College | Unique population of regulatory t cells that regulate tissue regeneration and wound healing |
| CN104768567B (zh) * | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
| JP2016519108A (ja) | 2013-04-18 | 2016-06-30 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０を疾病及び疾患の治療に用いる方法 |
| WO2014204816A2 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| US10098929B2 (en) | 2013-08-02 | 2018-10-16 | Children's Hospital Medical Center | Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan |
| CA2920679A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN105848674A (zh) | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| CA2963989A1 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
| EP3341012B1 (en) | 2015-08-25 | 2025-07-30 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929442A (en) | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| EP0280560B1 (en) | 1987-02-27 | 1994-05-11 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Membrane structure coated with low pI protein and methods of making and using |
| EP0454736A4 (en) * | 1989-01-20 | 1993-05-12 | The University Of Melbourne | Fibrinolysis |
| US5242902A (en) | 1989-09-06 | 1993-09-07 | The Regents Of The University Of California | Defensin peptide compositions and methods for their use |
| AU635377B2 (en) * | 1989-11-21 | 1993-03-18 | University Of Melbourne, The | Anti-inflammatory compositions and methods |
| ATE171625T1 (de) | 1990-04-11 | 1998-10-15 | Brigham & Womens Hospital | Therapeutische verwendung von actin-bindenden verbindungen |
| ES2085003T3 (es) * | 1991-01-10 | 1996-05-16 | Schering Corp | Uso de il-4 para mejorar la fase reparadora de la curacion y restaño de heridas y para mejorar la curacion de heridas infectadas y las heridas de mamiferos diabeticos. |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| AU8647991A (en) | 1991-08-26 | 1993-03-16 | State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The | Keratinocyte-derived conditioned medium as a source of growth factors |
| GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
| GB9207732D0 (en) * | 1992-04-06 | 1992-05-27 | Isis Innovation | Wound repair |
| WO1994027640A1 (en) * | 1993-05-27 | 1994-12-08 | The Regents Of The University Of Michigan | Method of treatment and prevention of immune complex-induced lung injury |
| NZ269663A (en) | 1993-07-26 | 1997-09-22 | Schering Corp | Agonists and antagonists of il-10 |
| AU710153B2 (en) * | 1994-03-29 | 1999-09-16 | Renovo Limited | Wound healing |
| EP1621206A1 (en) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| GB9516012D0 (en) | 1995-08-04 | 1995-10-04 | Univ Manchester | Pharmaceutical composition |
| GB2304045A (en) | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
-
1995
- 1995-08-09 GB GB9516287A patent/GB2304047A/en not_active Withdrawn
-
1996
- 1996-08-08 PT PT96926507T patent/PT871473E/pt unknown
- 1996-08-08 WO PCT/GB1996/001930 patent/WO1997005894A1/en not_active Ceased
- 1996-08-08 DE DE69625516T patent/DE69625516T2/de not_active Expired - Lifetime
- 1996-08-08 EP EP96926507A patent/EP0871473B1/en not_active Expired - Lifetime
- 1996-08-08 ES ES96926507T patent/ES2187665T3/es not_active Expired - Lifetime
- 1996-08-08 AU AU66660/96A patent/AU719089B2/en not_active Ceased
- 1996-08-08 DK DK96926507T patent/DK0871473T3/da active
- 1996-08-08 AT AT96926507T patent/ATE229814T1/de active
- 1996-08-08 JP JP50824697A patent/JP4050317B2/ja not_active Expired - Fee Related
- 1996-08-08 CA CA2229078A patent/CA2229078C/en not_active Expired - Fee Related
- 1996-08-08 ZA ZA9606744A patent/ZA966744B/xx unknown
- 1996-08-08 US US09/011,027 patent/US6387364B1/en not_active Expired - Lifetime
-
2002
- 2002-02-26 US US10/082,221 patent/US7052684B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6387364B1 (en) | 2002-05-14 |
| ZA966744B (en) | 1998-02-09 |
| JPH11510505A (ja) | 1999-09-14 |
| US20020128447A1 (en) | 2002-09-12 |
| AU6666096A (en) | 1997-03-05 |
| EP0871473B1 (en) | 2002-12-18 |
| DE69625516T2 (de) | 2003-09-25 |
| EP0871473A1 (en) | 1998-10-21 |
| DK0871473T3 (da) | 2003-04-14 |
| CA2229078C (en) | 2010-04-20 |
| ES2187665T3 (es) | 2003-06-16 |
| AU719089B2 (en) | 2000-05-04 |
| GB2304047A (en) | 1997-03-12 |
| GB9516287D0 (en) | 1995-10-11 |
| PT871473E (pt) | 2003-03-31 |
| CA2229078A1 (en) | 1997-02-20 |
| WO1997005894A1 (en) | 1997-02-20 |
| US7052684B2 (en) | 2006-05-30 |
| DE69625516D1 (de) | 2003-01-30 |
| ATE229814T1 (de) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4050317B2 (ja) | Ｉｌ−１０含有医薬組成物 | |
| US4808402A (en) | Method and compositions for modulating neovascularization | |
| Arend | Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. | |
| Bessis et al. | The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis | |
| EP0968723B1 (en) | Healing of wounds or fibrotic disorders using at least one agent against a growth factor | |
| JP4102437B2 (ja) | アクチビンおよびインヒビン刺激因子を含有する医薬組成物 | |
| US5202118A (en) | Method for promoting wound healing using IL-1 | |
| EP2572724A1 (de) | Behandlung von Fibrosen und Lebererkrankungen | |
| JP4189030B2 (ja) | 瘢痕の形成を減少するためのベータグリカンの使用 | |
| EP0393140B1 (en) | Topical wound-healing preparations comprising interleukin-1 proteins | |
| JPH11511160A (ja) | インターフェロン−ガンマインヒビター含有医薬組成物 | |
| EP2718456B1 (en) | Mitigation of cutaneous injury with il-12 | |
| US20090285775A1 (en) | Treatment of wounds using il-17b | |
| DE69209051T2 (de) | Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren | |
| WO2000057902A1 (en) | Method and pharmaceutical composition for wound healing | |
| EP2089050A2 (en) | Il- 17b for use in wound healing | |
| DE69916022T2 (de) | Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs | |
| WO1995007710A1 (en) | Remedy for wound | |
| US20080159979A1 (en) | Treatment of wounds using il-17b | |
| DE60019921T2 (de) | Verwendung von interleukin-11 zur behandlung von hämoragischem schock | |
| AU747598B2 (en) | Pharmaceutical composition containing stimulators of interferon-gamma | |
| SAHARA et al. | The Effect of GM-CSF of the Inhibition of Contraction of Excisional Wounds Caused by Bacterial Contamination | |
| HK1024419A (en) | Healing of wounds or fibrotic disorders using at least one agent against a growth factor | |
| WO2000068267A1 (en) | LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070907 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071030 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071129 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101207 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101207 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111207 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111207 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121207 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131207 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |